Skip to Content

Notice

Guidance for Industry: Gamma Irradiation of Blood and Blood Components: A Pilot Program for Licensing; Withdrawal of Guidance

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice; withdrawal.

SUMMARY:

The Food and Drug Administration (FDA) is announcing the withdrawal of a guidance that was issued on March 15, 2000.

DATES:

April 10, 2006.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Pamela Pope, Center for Biologics Evaluation and Research (HFM-17), Food and Drug Administration, 1401 Rockville Pike, suite 200N, Rockville, MD 20852-1448, 301-827-6210.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

In a notice published in the Federal Register of March 15, 2000 (65 FR 13982), FDA announced the availability of a guidance entitled “Guidance for Industry: Gamma Irradiation of Blood and Blood Components: A Pilot Program for Licensing.” This guidance described a Start Printed Page 18107pilot program in which biologics manufacturers could self-certify conformance to licensing criteria prescribed by FDA. This action was intended to reduce unnecessary burdens for industry without diminishing public health protection.

The guidance is being withdrawn because FDA has determined that there is a lack of industry interest in pursuing the pilot licensing program outlined in the guidance.

Start Signature

Dated: March 31, 2006.

Jeffrey Shuren,

Assistant Commissioner for Policy.

End Signature End Supplemental Information

[FR Doc. E6-5204 Filed 4-7-06; 8:45 am]

BILLING CODE 4160-01-S